statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D...

Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing

Medivir AB (publ) (OTCMKTS:MVRBF - Get Free Report) and Century Therapeutics (NASDAQ:IPSC - Get Free Report) are both medical companies, but which is the better business? We will contrast the two...

Head-To-Head Review: Century Therapeutics (NASDAQ:IPSC) and Medivir AB (publ) (OTCMKTS:MVRBF)

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN...

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Shares of Century Therapeutics, Inc. (NASDAQ:IPSC  Get Free Report) have been assigned a consensus rating of Moderate Buy from the six brokerages that are covering the company...

Century Therapeutics, Inc. (NASDAQ:IPSC) Given Consensus Recommendation of "Moderate Buy" by Brokerages

PHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...

Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Century Therapeutics (NASDAQ:IPSC  Free Report) had its price target upped by Canaccord Genuity Group from $22.00 to $24.00 in a research note issued to investors on Friday, Benzinga reports...

Century Therapeutics (NASDAQ:IPSC) Price Target Increased to $24.00 by Analysts at Canaccord Genuity Group

Century Therapeutics (NASDAQ:IPSC  Get Free Report) had its price objective upped by analysts at Canaccord Genuity Group from $22.00 to $24.00 in a research report issued on Friday, Benzinga...

Canaccord Genuity Group Increases Century Therapeutics (NASDAQ:IPSC) Price Target to $24.00

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Century Therapeutics price target raised by $2 at Canaccord, here's why

- Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that...

Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

Innate Pharma (OTCMKTS:IPHYF  Get Free Report) and Century Therapeutics (NASDAQ:IPSC  Get Free Report) are both small-cap medical companies, but which is the better stock? We will...

Century Therapeutics (NASDAQ:IPSC) vs. Innate Pharma (OTCMKTS:IPHYF) Head to Head Survey

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Volume	94,782.00
52-Wk High	$5.51
52-Wk Low	$1.28

IPSC Century Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals